Precision treatment study for advanced bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether treatments chosen based on the specific gene changes in your bile duct cancer can work better. It's for people with advanced cancer that hasn't responded to standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery, and your tumor has a specific gene change (like FGFR2, IDH1, HER2, BRAF, or others).
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are able to take care of yourself and do light activities.
- Your liver and blood cell counts are good enough, and you have no serious heart, lung, or kidney problems.
- You have not had major surgery in the last month, and you do not have other active cancers or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
This trial tests whether adding a targeted therapy (anlotinib) to standard chemo plus an immunotherapy (camrelizumab) is more effective than chemo plus immunotherapy alone for advanced gallbladder or bile duct cancers that cannot be removed by surgery.
This Phase 3 trial matches people with advanced bile duct cancer or gallbladder cancer to a specific targeted medicine based on their tumor’s lab results. It aims to improve disease control by using the right drug for the specific changes found in the cancer.
This Phase 2 trial tests a combination of lenvatinib, an immunotherapy drug (tislelizumab), and chemotherapy (gemcitabine plus cisplatin) for advanced bile duct cancer that cannot be removed with surgery. It aims to see whether this treatment can shrink tumors and improve outcomes, especially for people who have not yet had immunotherapy.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.
Hear when a new Advanced Cholangiocarcinoma (Part 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.